Dengue PPTs and 600 free full text articles

Dengue: Epidemiology
Scott B Halstead, MD
http://www.pitt.edu/_Part1
http://www.pitt.edu/ Part2

Dengue & Dengue Hemorrhagic Fever
DR.I.SELVARAJ, IRMS
http://www.pitt.edu/

Dengue Fever
Amber Beg
http://courses.bio.unc.edu

Translational Control of Dengue Viral Genome: Role of 3’ UTR & CS1
Anna Carmona
http://oregonstate.edu

Dengue Ontology, User-Developer perspective
http://ontology.buffalo.edu

Dengue
http://www.reeme.arizona.edu

Multi-country Study of Costs of Dengue among Ambulatory and Hospitalized Patients
http://people.brandeis.edu/

Dengue and Dengue Hemorrhagic Fever at the TX-MX Border
Mary Hayden
http://www.asp.ucar.edu/

Dengue Virus
Inna Gnipp and  Hamza Iqbal
http://www2.yk.psu.edu

Dengue Virus: No One Is Safe
Caitlin Reed
http://www.science.smith.edu

Overview: What is Dengue
http://www.hawaii.edu

Dengue Fever
Brian Rochana, Aurora Cardenas, David Marquez
http://instructional1.calstatela.edu

Dengue
http://www2.jabsom.hawaii.edu

Dengue fever
Shuchismita Dutta, Mary Elizabeth Wilson, MD
http://dev.drclas.harvard.edu

600 Free full text published articles on Dengue

1. [Screening and identification of dengue virus type 2-specific antigens].
2. Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1.
3. Outbreak of dengue virus serotype-2 (DENV-2) of Cambodian origin in Manipur, India - Association with meteorological factors.
4. Evaluation of the WHO revised criteria for classification of clinical disease severity in acute adult dengue infection.
5. Weather-Driven Variation in Dengue Activity in Australia Examined Using a Process-Based Modeling Approach.
6. A Cluster-Randomized Trial of Insecticide-Treated Curtains for Dengue Vector Control in Thailand.
7. Sculpting humoral immunity through dengue vaccination to enhance protective immunity.
8. The impact of insecticide-treated school uniforms on dengue infections in school-aged children: study protocol for a randomised controlled trial in Thailand.
9. Coinfection dengue and melioidosis infection.
10. Dengue Virus Type 2 Modulates Endothelial Barrier Function through CD73.
11. Temporal analysis of the relationship between dengue and meteorological variables in the city of Rio de Janeiro, Brazil, 2001-2009.
12. [Uses and influence of health evaluation in two studies on the Brazilian National Dengue Fever Control Program].
13. Dengue virus type 4 in Niterói, Rio de Janeiro: the role of molecular techniques in laboratory diagnosis and entomological surveillance.
14. Controlling dengue with vaccines in Thailand.
15. Effectiveness of Ultra-Low Volume Nighttime Applications of an Adulticide against Diurnal Aedes albopictus, a Critical Vector of Dengue and Chikungunya Viruses.
16. Climate change, population immunity, and hyperendemicity in the transmission threshold of dengue.
17. Novel antiviral activity of baicalein against dengue virus.
18. Dynamic epidemiological models for dengue transmission: a systematic review of structural approaches.
19. Higher Risk of Infection with Dengue at the Weekend among Male Singaporeans.
20. A data-driven epidemiological prediction method for dengue outbreaks using local and remote sensing data.
21. HLA-A*0201-restricted CD8+ T-cell epitopes identified in dengue viruses.
22. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial.
23. Detection of dengue group viruses by fluorescence in situ hybridization.
24. Dengue vector management using insecticide treated materials and targeted interventions on productive breeding-sites in Guatemala.
25. Optimal lead time for dengue forecast.
26. Isotope Coded Protein Labeling analysis of plasma specimens from acute severe dengue fever patients.
27. Students knowledge as a contribution to dengue control programs with a great interest.
28. Dengue hemorrhagic fever and severe thrombocytopenia in a patient on mandatory anticoagulation; balancing two life threatening conditions; a case report.
29. [Epidemiological dynamics of dengue on Easter Island].
30. Protegrin-1 Inhibits Dengue NS2B-NS3 Serine Protease and Viral Replication in MK2 Cells.
31. Phylogeography of dengue virus serotype 4, Brazil, 2010-2011.
32. Sources of dengue viruses imported into queensland, australia, 2002-2010.
33. Seroprevalence of Antibodies against Chikungunya, Dengue, and Rift Valley Fever Viruses after Febrile Illness Outbreak, Madagascar.
34. Dengue infection and maternal mortality.
35. Pathogenesis of severe dengue infection.
36. Comparative Expression Profiles of Midgut Genes in Dengue Virus Refractory and Susceptible Aedes aegypti across Critical Period for Virus Infection.
37. Aging Field Collected Aedes aegypti to Determine Their Capacity for Dengue Transmission in the Southwestern United States.
38. Sympathetic dysfunction as a cause for hypotension in dengue shock syndrome.
39. Hepatic involvement in dengue Fever in children.
40. Ecologic and sociodemographic risk determinants for dengue transmission in urban areas in Thailand.
41. Intrahepatic infiltrating NK and CD8 T cells cause liver cell death in different phases of dengue virus infection.
42. Dengue antibodies in blood donors.
43. Hematological and biochemical findings in patients with dengue fever: a current issue.
44. Dengue: profile of hematological and biochemical dynamics.
45. Analyzing the spatio-temporal relationship between dengue vector larval density and land-use using factor analysis and spatial ring mapping.
46. Detection of dengue virus 4 from central India.
47. Dengue in India.
48. Coronary artery bypass grafting and dengue fever.
49. The stem region of premembrane protein plays an important role in the virus surface protein rearrangement during dengue maturation.
50. Diarrhea and dengue control in rural primary schools in Colombia: study protocol for a randomized controlled trial.
51. Expanded dengue syndrome: subacute thyroiditis and intracerebral hemorrhage.
52. Clinical Profile of Concurrent Dengue Fever and Plasmodium vivax Malaria in the Brazilian Amazon: Case Series of 11 Hospitalized Patients.
53. An operative dengue risk stratification system in Argentina based on geospatial technology.
54. Diagnosis of dengue: an update.
55. Q&A session 06 October 2011: I International Symposium on Dengue, FMUSP, São Paulo.
56. Designing a vaccination strategy against dengue.
57. Development of Sanofi Pasteur tetravalent dengue vaccine.
58. Laboratory diagnosis for dengue.
59. Clinical experience in dengue: experience of specialized service.
60. Global dengue epidemiology trends.
61. Spatial and Temporal Patterns of Dengue Transmission along a Red Sea Coastline: A Longitudinal Entomological and Serological Survey in Port Sudan City.
62. Simple Clinical and Laboratory Predictors of Chikungunya versus Dengue Infections in Adults.
63. Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials.
64. Evidence in australia for a case of airport dengue.
65. Molecular basis for nucleotide conservation at the ends of the dengue virus genome.
66. Panophthalmitis in dengue Fever.
67. Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis.
68. Assessing the temporal modelling for prediction of dengue infection in northern and north-eastern, Thailand.
69. Dengue outbreaks in high-income area, kaohsiung city, taiwan, 2003-2009.
70. Molecular characterisation of dengue virus type 1 reveals lineage replacement during circulation in Brazilian territory.
71. [Screening of dengue II virus-binding molecules from Aedes albopictus C6/36 cells].
72. Spatial distribution of dengue in the city of Cruzeiro, São Paulo State, Brazil: use of geoprocessing tools.
73. Seroprevalence and trend of dengue cases admitted to a government hospital, delhi - 5-year study (2006-2010): a look into the age shift.
74. Origin and evolution of dengue virus type 3 in Brazil.
75. Differential requirements in endocytic trafficking for penetration of dengue virus.
76. Dengue virus presence and surveillance in Okinawa (Review).
77. Autoimmune and dengue fever.
78. The interactive roles of Aedes aegypti super-production and human density in dengue transmission.
79. The importance of long-term social research in enabling participation and developing engagement strategies for new dengue control technologies.
80. Roles for endothelial cells in dengue virus infection.
81. Pancreatitis and MODS Due to Scrub Typhus and Dengue Co-Infection.
82. Reviewing the development, evidence base, and application of the revised dengue case classification.
83. Evaluation of platelets as predictive parameters in dengue Fever.
84. Dengue fever in South Korea, 2006-2010.
85. The burden of dengue: Jundiaí, Brazil - January 2010.
86. A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan.
87. Ultrasensitive cDNA detection of dengue virus RNA using electrochemical nanoporous membrane-based biosensor.
88. Dengue virus serotype 2 blocks extracellular signal-regulated kinase and nuclear factor-κB activation to downregulate cytokine production.
89. Circulation of Dengue virus-1 (DENV-1) serotype in Delhi, during 2010-11 after Dengue virus-3 (DENV-3) predominance: a single centre hospital-based study.
90. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
91. Climatic factors influencing dengue cases in Dhaka city: a model for dengue prediction.
92. Advances in developing a climate based dengue outbreak models in Dhaka, Bangladesh: challenges & opportunities.
93. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
94. Refining the global spatial limits of dengue virus transmission by evidence-based consensus.
95. Operational efficiency and sustainability of vector control of malaria and dengue: descriptive case studies from the Philippines.
96. Expression profile of genes during resistance reversal in a temephos selected strain of the dengue vector, Aedes aegypti.
97. Treatment of dengue fever.
98. Airport sentinel surveillance and entry quarantine for dengue infections following a fever screening program in Taiwan.
99. Dengue encephalitis in children.
100. Effects of short-course oral corticosteroid therapy in early dengue infection in vietnamese patients: a randomized, placebo-controlled trial.
101. Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006-2009.
102. Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells.
103. [A school program for dengue control in Honduras: from knowledge to action].
104. Wolbachia induces density-dependent inhibition to dengue virus in mosquito cells.
105. Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses.
106. Dengue fever occurrence and vector detection by larval survey, ovitrap and MosquiTRAP: a space-time clusters analysis.
107. Occurrence of natural vertical transmission of dengue-2 and dengue-3 viruses in Aedes aegypti and Aedes albopictus in Fortaleza, Ceará, Brazil.
108. Serratia odorifera a midgut inhabitant of Aedes aegypti mosquito enhances its susceptibility to dengue-2 virus.
109. Clinical profile of dengue infection at a teaching hospital in North India.
110. Dengue and psychiatry disorder.
111. Bioinformatics prediction of siRNAs as potential antiviral agents against dengue viruses.
112. Comparison of performance of serum and plasma in panbio dengue and Japanese encephalitis virus enzyme-linked immunosorbent assays.
113. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.
114. Fine scale spatiotemporal clustering of dengue virus transmission in children and Aedes aegypti in rural Thai villages.
115. Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever.
116. The dengue vector Aedes aegypti contains a functional high mobility group box 1 (HMGB1) protein with a unique regulatory C-terminus.
117. Paralytic squint due to abducens nerve palsy: a rare consequence of dengue fever.
118. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
119. Dengue hemorrhagic fever in an adult traveler returning to Japan.
120. Evaluation of dengue-related health information on the internet.
121. Is temperature the main cause of dengue rise in non- endemic countries? The case of Argentina.
122. An evaluation of dried blood spots and oral swabs as alternative specimens for the diagnosis of dengue and screening for past dengue virus exposure.
123. Dengue virus targets the adaptor protein MITA to subvert host innate immunity.
124. Simultaneous circulation of all four dengue serotypes in Manaus, State of Amazonas, Brazil in 2011.
125. Genetic diversity of dengue virus serotypes 1 and 2 in the State of Paraná, Brazil, based on a fragment of the capsid/premembrane junction region.
126. Dengue in Brazil.
127. High Level of Awareness but Poor Practices Regarding Dengue Fever Control: A Cross-sectional Study from North India.
128. Dengue: A reemerging concern for travelers.
129. Prophylactic platelets in dengue: survey responses highlight lack of an evidence base.
130. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children.
131. Co-circulation of two genotypes of dengue virus serotype 3 in Guangzhou, China, 2009.
132. Gene amplification, ABC transporters and cytochrome P450s: unraveling the molecular basis of pyrethroid resistance in the dengue vector, Aedes aegypti.
133. Phylogenetic relationship of dengue virus type 3 isolated in Brazil and Paraguay and global evolutionary divergence dynamics.
134. Electronic event-based surveillance for monitoring dengue, Latin America.
135. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement.
136. Spatiotemporal analysis of indigenous and imported dengue fever cases in Guangdong province, China.
137. Hypokalemic quadriparesis: An unusual manifestation of dengue fever.
138. Leptospirosis prevalence in patients with initial diagnosis of dengue.
139. Clinical relevance and discriminatory value of elevated liver aminotransferase levels for dengue severity.
140. Early dengue virus protein synthesis induces extensive rearrangement of the endoplasmic reticulum independent of the UPR and SREBP-2 pathway.
141. [Serum platelet-activating factor acetylhydrolase activity in dengue patients of African or mestizo descendency].
142. Fluid management for dengue in children.
143. The revised WHO dengue case classification: does the system need to be modified?
144. Dengue infections in travellers.
145. Dengue fever and dengue haemorrhagic fever in adolescents and adults.
146. The dengue situation in Africa.
147. Dengue: an escalating public health problem in Latin America.
148. Community participation in the prevention and control of dengue: the patio limpio strategy in Mexico.
149. Controversies in dengue pathogenesis.
150. Proceedings of the dengue symposium at the 9th international congress of tropical pediatrics.
151. Proceedings of the Dengue Congress at the 9th International Congress of Tropical Pediatrics in Bangkok in October 2011.
152. [Maternal mortality and impact of dengue in Southeast Brazil: an ecological study, 2001-2005].
153. Imunocompetent mice model for dengue virus infection.
154. Awareness of changing trends in epidemiology of dengue fever is essential for epidemiological surveillance.
155. Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs?
156. Unfurling the rationale use of platelet transfusion in dengue Fever.
157. Revealing the microscale spatial signature of dengue transmission and immunity in an urban population.
158. Re-emergence of dengue in Reunion, France, January to April 2012.
159. Assessing the risk for dengue fever based on socioeconomic and environmental variables in a geographical information system environment.
160. [The status of the dengue surveillance system in a Colombian municipality].
161. Surveillance of dengue fever virus: a review of epidemiological models and early warning systems.
162. Lethal effects of Aspergillus niger against mosquitoes vector of filaria, malaria, and dengue: a liquid mycoadulticide.
163. Vertical transmission of dengue virus in Aedes aegypti collected in Surabaya, Indonesia, during 2008-2011.
164. Transfusion requirement during dengue fever epidemic in a rural medical college in south India.
165. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.
166. Innate immunity evasion by Dengue virus.
167. Dengue infection and miscarriage: a prospective case control study.
168. Acute disseminated encephalomyelitis and dengue fever: comment.
169. Thirty years after the Cuban hemorrhagic dengue epidemic of 1981.
170. Susceptibility and response of human blood monocyte subsets to primary dengue virus infection.
171. Designing cyclopentapeptide inhibitor as potential antiviral drug for dengue virus ns5 methyltransferase.
172. [Cultural dimensions of dengue that help or hinder its prevention in Mexico].
173. Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study.
174. Correlation of serotype-specific dengue virus infection with clinical manifestations.
175. Development of a humanized antibody with high therapeutic potential against dengue virus type 2.
176. Linking oviposition site choice to offspring fitness in Aedes aegypti: consequences for targeted larval control of dengue vectors.
177. Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13.
178. Elevated levels of vitamin D and deficiency of mannose binding lectin in dengue hemorrhagic fever.
179. Novel ATP-independent RNA annealing activity of the dengue virus NS3 helicase.
180. Economic cost of dengue in Puerto Rico.
181. The economic burden of dengue.
182. [Geographic distribution of dengue fever cases in flooded zones from Villahermosa, Tabasco, in 2010].
183. Is dengue and malaria co-infection more severe than single infections? A retrospective matched-pair study in French Guiana.
184. Increasing Role of Roof Gutters as Aedes aegypti (Diptera: Culicidae) Breeding Sites in Guadeloupe (French West Indies) and Consequences on Dengue Transmission and Vector Control.
185. Spatial pattern of 2009 dengue distribution in Kuala Lumpur using GIS application.
186. Diffusion pattern and hotspot detection of dengue in belo horizonte, minas gerais, Brazil.
187. Evaluation of 15 Local Plant Species as Larvicidal Agents Against an Indian Strain of Dengue Fever Mosquito, Aedes aegypti L. (Diptera: Culicidae).
188. Interpretation of the presence of IgM and IgG antibodies in a rapid test for dengue: analysis of dengue antibody prevalence in Fortaleza City in the 20th year of the epidemic.
189. Hydroclimatological variability and dengue transmission in Dhaka, Bangladesh: a time-series study.
190. Synergistic interactions between the NS3(hel) and E proteins contribute to the virulence of dengue virus type 1.
191. Dengue deaths in Puerto Rico: lessons learned from the 2007 epidemic.
192. Additive protection by antioxidant and apoptosis-inhibiting effects on mosquito cells with dengue 2 virus infection.
193. Comparative evaluation of permissiveness to dengue virus serotype 2 infection in primary rodent macrophages.
194. Peritoneal dialysis in dengue shock syndrome may be detrimental.
195. Dengue virus entry as target for antiviral therapy.
196. A predictive spatial model to quantify the risk of air-travel-associated dengue importation into the United States and europe.
197. Molecular typing of dengue virus circulating in kolkata, India in 2010.
198. Fatal human co-infection with Leptospira spp. and dengue virus, Puerto Rico, 2010.
199. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.
200. Effectiveness of Space Spraying on the Transmission of Dengue/Dengue Hemorrhagic Fever (DF/DHF) in an Urban Area of Southern Thailand.
201. Spontaneous splenic rupture in dengue fever with non-fatal outcome in an adult.
202. Clinical Manifestations and Management of Dengue/DHF/DSS.
203. Host genetic susceptibility to severe dengue infection.
204. Issues related to recent dengue vaccine development.
205. Dengue and soluble mediators of the innate immune system.
206. T-cell responses to dengue virus in humans.
207. Dengue virus receptor.
208. Quasispecies of dengue virus.
209. Dengue Vectors and their Spatial Distribution.
210. Imported dengue fever/dengue hemorrhagic fever cases in Japan.
211. Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century.
212. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
213. Apropos "Evaluation of dengue NS1 antigen detection for diagnosis in public health laboratories, São Paulo State, 2009".
214. Emergence of dengue virus 4 genotype II in Guangzhou, China, 2010: survey and molecular epidemiology of one community outbreak.
215. Development and evaluation of an enzyme-linked immunosorbent assay for dengue capsid.
216. Small-molecule inhibitors of dengue-virus entry.
217. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.
218. Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries.
219. Comparing statistical models to predict dengue fever notifications.
220. Pinpointing P450s associated with pyrethroid metabolism in the dengue vector, Aedes aegypti: developing new tools to combat insecticide resistance.
221. Assessing the potential of a candidate dengue vaccine with mathematical modeling.
222. IFITM proteins restrict antibody-dependent enhancement of dengue virus infection.
223. RNA sensors enable human mast cell anti-viral chemokine production and IFN-mediated protection in response to antibody-enhanced dengue virus infection.
224. Eventual role of asymptomatic cases of dengue for the introduction and spread of dengue viruses in non-endemic regions.
225. Dengue virus infection of the Aedes aegypti salivary gland and chemosensory apparatus induces genes that modulate infection and blood-feeding behavior.
226. A prospective cohort study to evaluate peridomestic infection as a determinant of dengue transmission: protocol.
227. Dengue in patients with central nervous system manifestations, Brazil.
228. Dengue and US military operations from the Spanish-American War through today.
229. Surveillance for West Nile, dengue, and chikungunya virus infections, Veneto Region, Italy, 2010.
230. Lessons learned during dengue outbreaks in the United States, 2001-2011.
231. Role of microparticles in dengue virus infection and its impact on medical intervention strategies.
232. RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cells.
233. Dengue virus infection perturbs lipid homeostasis in infected mosquito cells.
234. DengueTools: innovative tools and strategies for the surveillance and control of dengue.
235. Acute pancreatitis in dengue hemorrhagic fever.
236. Construction of the discourse on dengue fever in the media.
237. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans.
238. Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection.
239. A tetravalent dengue nanoparticle stimulates antibody production in mice.
240. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2.
241. The magnitude of dengue virus NS1 protein secretion is strain dependent and does not correlate with severe pathologies in the mouse infection model.
242. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.
243. HLA-A*01 allele: a risk factor for dengue haemorrhagic fever in Brazil's population.
244. Early clinical features of dengue virus infection in nicaraguan children: a longitudinal analysis.
245. Reciprocal tripartite interactions between the Aedes aegypti midgut microbiota, innate immune system and dengue virus influences vector competence.
246. A fatal combo of dengue shock syndrome with acute subdural hematoma.
247. Phylogenetic reconstruction of dengue virus type 2 in Colombia.
248. Upregulation of MHC class I expression following dengue virus infection: the mechanism at the promoter level.
249. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells.
250. Dengue infection in children in Ratchaburi, Thailand: a cohort study. II. Clinical manifestations.
251. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.
252. Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus.
253. Strain Variation in the Transcriptome of the Dengue Fever Vector, Aedes aegypti.
254. Simple Prognostic Criteria can Definitively Identify Patients who Develop Severe Versus Non-Severe Dengue Disease, or Have Other Febrile Illnesses.
255. The relative importance of innate immune priming in Wolbachia-mediated dengue interference.
256. Re: Dengue Haemorrhagic Fever presenting as Acute Abdomen.
257. SARIMA for predicting the cases numbers of dengue.
258. Severe coinfection of melioidosis and dengue fever in Northeastern Brazil: first case report.
259. First isolation of Dengue 4 in the state of São Paulo, Brazil, 2011.
260. Fatal dengue hemorrhagic fever in adults: emphasizing the evolutionary pre-fatal clinical and laboratory manifestations.
261. Association of mast cell-derived VEGF and proteases in Dengue shock syndrome.
262. Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999-2003).
263. Insecticide resistance in the dengue vector Aedes aegypti from Martinique: distribution, mechanisms and relations with environmental factors.
264. Comparison of real-time SYBR green dengue assay with real-time taqman RT-PCR dengue assay and the conventional nested PCR for diagnosis of primary and secondary dengue infection.
265. [Integrated prevention and control strategy for dengue in Mesoamerica].
266. Autoimmune features caused by dengue fever: a case report.
267. Diaphragmatic paralysis: a rare consequence of dengue fever.
268. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans.
269. Animal models of dengue virus infection.
270. The human antibody response to dengue virus infection.
271. Climate-based models for understanding and forecasting dengue epidemics.
272. Acute neuromuscular weakness associated with dengue infection.
273. Dengue infection: An emerging cause of neuromuscular weakness.
274. Concurrent infection of dengue fever and hepatitis A infection: A case report.
275. Neurological complications of dengue fever: Experience from a tertiary center of north India.
276. Two cases of dengue meningitis: a rare first presentation.
277. Role of complement in dengue virus infection: protection or pathogenesis?
278. Internally controlled, generic real-time PCR for quantification and multiplex real-time PCR with serotype-specific probes for serotyping of dengue virus infections.
279. Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1β and CCL2/MCP-1 in dengue fever and parvovirosis.
280. Risk for emergence of dengue and chikungunya virus in Israel.
281. Dengue surveillance among French military in Africa.
282. Unsuspected dengue and acute febrile illness in rural and semi-urban southern Sri Lanka.
283. Shift in the transmission pattern of dengue serotypes and concurrent infection with more than one dengue virus serotype.
284. Psychiatry disorders and dengue: is there a relationship?
285. Maternal and fetal outcome of dengue fever in pregnancy.
286. When less is more: can we abandon prophylactic platelet transfusion in Dengue fever?
287. Dengue knowledge, attitudes, and practices among primary care physicians in Singapore.
288. Subcutaneous infection with non-mouse adapted Dengue virus D2Y98P strain induces systemic vascular leakage in AG129 mice.
289. Dengue research in Singapore marking the inaugural ASEAN Dengue Day.
290. Clinical and virological study of dengue cases and the members of their households: the multinational DENFRAME Project.
291. Epstein-Barr virus co-infection in a patient with dengue fever presenting with post-infectious cerebellitis: a case report.
292. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
293. A local outbreak of dengue caused by an imported case in Dongguan China.
294. Aedes albopictus and the reemergence of Dengue.
295. Dengue outbreak in Key West, Florida, USA, 2009.
296. Daily newspaper view of dengue fever epidemic, Athens, Greece, 1927-1931.
297. Complete genome sequence of a Dengue virus serotype 4 strain isolated in Roraima, Brazil.
298. Screening of anti-dengue activity in methanolic extracts of medicinal plants.
299. Replication in cells of hematopoietic origin is necessary for Dengue virus dissemination.
300. Dengue vaccines: closer but not there yet.
301. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans.
302. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay.
303. Clinical and laboratory findings in patients with dengue associated with hepatopathy.
304. Dengue rapid strip test: a Sri Lankan experience.
305. Prevalence of dengue and chickungunya fever and their co-infection.
306. Coronary artery bypass grafting and dengue fever.
307. Hantavirus infection in suspected dengue cases from State of Ceará, Brazil.
308. Epidemiological aspects of dengue in Aracaju, State of Sergipe, Brazil.
309. Dengue hemorrhagic fever complicated by pancreatitis.
310. Hemophagocytic syndrome in classic dengue Fever.
311. [Death from dengue fever as a sentinel event for evaluation of quality of healthcare: a case study in two municipalities in Northeast Brazil, 2008].
312. Dengue virus type 4 phylogenetics in Brazil 2011: looking beyond the veil.
313. Recent emergence of dengue virus serotype 4 in French Polynesia results from multiple introductions from other South Pacific Islands.
314. Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection.
315. IFN-γ production depends on IL-12 and IL-18 combined action and mediates host resistance to dengue virus infection in a nitric oxide-dependent manner.
316. Novel, meso-substituted cationic porphyrin molecule for photo-mediated larval control of the dengue vector Aedes aegypti.
317. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore.
318. Population dynamics of Aedes aegypti and dengue as influenced by weather and human behavior in San Juan, Puerto Rico.
319. Overview of plant-derived vaccine antigens: Dengue virus.
320. Antiviral activity of four types of bioflavonoid against dengue virus type-2.
321. Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2.
322. Guillain-Barré syndrome and dengue.
323. Co-infection of Dengue virus by serotypes 3 and 4 in patients from Amazonas, Brazil.
324. Evaluation of dengue NS1 antigen detection for diagnosis in public health laboratories, São Paulo State, 2009.
325. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection.
326. Complement-mediated neutralization of dengue virus requires mannose-binding lectin.
327. Label-free electrochemical detection of the specific oligonucleotide sequence of dengue virus type 1 on pencil graphite electrodes.
328. Utility of the tourniquet test and the white blood cell count to differentiate dengue among acute febrile illnesses in the emergency room.
329. Dengue maculopathy in a traveler.
330. Inhibition of dengue virus entry and multiplication into monocytes using RNA interference.
331. Laboratory-acquired dengue virus infection--a case report.
332. Dengue virus capsid protein binding to hepatic lipid droplets (LD) is potassium ion dependent and is mediated by LD surface proteins.
333. Dengue-1 virus clade replacement in Thailand associated with enhanced mosquito transmission.
334. Seasonal communication about dengue fever in educational groups in primary healthcare.
335. Evaluation of students' knowledge as a contribution to dengue control programs.
336. Wolbachia induces reactive oxygen species (ROS)-dependent activation of the Toll pathway to control dengue virus in the mosquito Aedes aegypti.
337. Wolbachia strain wMel induces cytoplasmic incompatibility and blocks dengue transmission in Aedes albopictus.
338. Neuralgic amyotrophy associated with dengue fever: case series of three patients.
339. Association of platelet count and serological markers of dengue infection- importance of NS1 antigen.
340. Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein.
341. Primary and probable secondary dengue virus (DV) infection rates in relation to age among DV IgM-positive patients residing in the United States mainland versus the Caribbean islands.
342. Modeling spatio-temporal risk changes in the incidence of Dengue fever in Saudi Arabia: a geographical information system case study.
343. Global cross-talk of genes of the mosquito Aedes aegypti in response to dengue virus infection.
344. Mosquito-associated dengue virus, Key West, Florida, USA, 2010.
345. New dengue virus type 1 genotype in Colombo, Sri Lanka.
346. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes.
347. High-resolution analysis of intrahost genetic diversity in dengue virus serotype 1 infection identifies mixed infections.
348. Re: dengue haemorrhagic Fever presenting as acute abdomen.
349. Simultaneous Detection of Dengue NS1 Antigen, IgM plus IgG and Platelet Enumeration during an Outbreak.
350. Evaluation of the traditional and revised WHO classifications of Dengue disease severity.
351. Unusual dengue virus 3 epidemic in Nicaragua, 2009.
352. Displacement of the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in Surabaya, Indonesia 2008-2010.
353. Clinical profile of dengue infection in patients with hematological diseases.
354. Circulation of different lineages of dengue virus type 2 in Central America, their evolutionary time-scale and selection pressure analysis.
355. Uncoupling cis-Acting RNA elements from coding sequences revealed a requirement of the N-terminal region of dengue virus capsid protein in virus particle formation.
356. Next-generation dengue vaccines: novel strategies currently under development.
357. [Reducing hospitalization with the use of a dengue management algorithm in Colombia].
358. Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice.
359. Validation of probability equation and decision tree in predicting subsequent dengue hemorrhagic fever in adult dengue inpatients in Singapore.
360. Toxicological properties of several medicinal plants from the Himalayas (India) against vectors of malaria, filariasis and dengue.
361. Factors influencing the seasonal abundance of Aedes (Stegomyia) aegypti and the control strategy of dengue and dengue haemorrhagic fever in Thanlyin Township, Yangon City, Myanmar.
362. Aedes larval population dynamics and risk for dengue epidemics in Malaysia.
363. Optimal timing of insecticide fogging to minimize dengue cases: modeling dengue transmission among various seasonalities and transmission intensities.
364. Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength.
365. Ligand-bound structures of the dengue virus protease reveal the active conformation.
366. Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines.
367. [Knowledge, attitudes and community practice during an outbreak of dengue in a town in Colombia, 2010].
368. [Climatic factors and cases of dengue in Monteria, Colombia: 2003-2008].
369. [Classical dengue transmission dynamics involving mechanical control and prophylaxis].
370. Estimation of dengue virus IgM persistence using regression analysis.
371. Antiviral agents targeting glycans on dengue virus E-glycoprotein.
372. Prevalence and insecticide susceptibility of dengue vectors in the district of Batticaloa in eastern Sri Lanka.
373. Dengue and rhabdomyolysis.
374. Analysis of RNA binding by the dengue virus NS5 RNA capping enzyme.
375. Elevated levels of cell-free circulating DNA in patients with acute dengue virus infection.
376. Spatial patterns and socioecological drivers of dengue fever transmission in Queensland, Australia.
377. Dengue encephalitis.
378. Evaluation of six commercial point-of-care tests for diagnosis of acute dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to achieve acceptable levels of accuracy.
379. Potential impact of a presumed increase in the biting activity of dengue-virus-infected Aedes aegypti (Diptera: Culicidae) females on virus transmission dynamics.
380. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1.
381. Dengue virus serotype 4, Roraima State, Brazil.
382. A model framework to estimate impact and cost of genetics-based sterile insect methods for dengue vector control.
383. Functional RNA elements in the dengue virus genome.
384. Dengue--quo tu et quo vadis?
385. Dengue virus and autophagy.
386. The complexity of antibody-dependent enhancement of dengue virus infection.
387. ISG15 facilitates cellular antiviral response to dengue and west nile virus infection in vitro.
388. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand.
389. Insights into the internalization and retrograde trafficking of Dengue 2 virus in BHK-21 cells.
390. Predicting the number of cases of dengue infection in Ribeirão Preto, São Paulo State, Brazil, using a SARIMA model.
391. Quantifying the emergence of dengue in Hanoi, Vietnam: 1998-2009.
392. Pleural effusion and ultrasonography in dengue Fever.
393. Quality of life among adults with confirmed dengue in Brazil.
394. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.
395. Dengue Haemorrhagic Fever presenting as Acute Abdomen.
396. Apropos "Dengue virus immunoglobulin M detection in a reference laboratory setting during the 2010 dengue virus outbreak on Caribbean islands".
397. Dengue encephalopathy.
398. B-cell responses during primary and secondary dengue virus infections in humans.
399. Population density, water supply, and the risk of dengue fever in Vietnam: cohort study and spatial analysis.
400. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design.
401. Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome) following dengue fever.
402. Emergence of dengue in Andaman & Nicobar archipelago: eco-epidemiological perspective.
403. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue.
404. Dengue virus capsid protein binds core histones and inhibits nucleosome formation in human liver cells.
405. Alterations in the Aedes aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses.
406. Serotype and genotype analysis of dengue virus by sequencing followed by phylogenetic analysis using samples from three mini outbreaks-2007-2009 in Pakistan.
407. Managing patients with dengue fever during an epidemic: the importance of a hydration tent and of a multidisciplinary approach.
408. Strategies adopted to overcome dengue crisis at a hospital based blood bank.
409. Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles.
410. Janus kinase/signal transducer and activator of transcription 3 signaling pathway is crucial in chemokine production from hepatocytes infected by dengue virus.
411. Development of ASSURE Dengue IgA Rapid Test for the Detection of Anti-dengue IgA from Dengue Infected Patients.
412. Dextran fractional clearance studies in acute dengue infection.
413. The value of educational messages embedded in a community-based approach to combat dengue Fever: a systematic review and meta regression analysis.
414. Utility of IgM/IgG ratio and IgG avidity for distinguishing primary and secondary dengue virus infections using sera collected more than 30 days after disease onset.
415. [Inter-sector social mobilization for dengue control in Bahia State, Brazil].
416. Inhibition of dengue virus by targeting viral NS4B protein.
417. [Dengue: epidemiological aspects and the first outbreak in the Middle Solimões Region of Coari in the State of Amazonas from 2008 to 2009].
418. A SARIMA forecasting model to predict the number of cases of dengue in Campinas, State of São Paulo, Brazil.
419. Dengue fever in a patient recovering from coronary artery bypass grafting.
420. The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly.
421. Competitive inhibitor of cellular α-glucosidases protects mice from lethal dengue virus infection.
422. Using geographically weighted regression (GWR) to explore spatial varying relationships of immature mosquitoes and human densities with the incidence of dengue.
423. A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection.
424. Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome.
425. Dengue--how best to classify it.
426. Prediction of dengue incidence using search query surveillance.
427. First report of sylvatic DENV-2-associated dengue hemorrhagic fever in West Africa.
428. Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-β in cultured hepatoma cells.
429. In vitro activation and enzyme kinetic analysis of recombinant midgut serine proteases from the Dengue vector mosquito Aedes aegypti.
430. A novel single-dose dengue subunit vaccine induces memory immune responses.
431. Could peak proteinuria determine whether patient with dengue fever develop dengue hemorrhagic/dengue shock syndrome?--a prospective cohort study.
432. Decay and persistence of maternal dengue antibodies among infants in Bangkok.
433. Toll-like receptor 4 polymorphisms in dengue virus-infected children.
434. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.
435. Parameterization and sensitivity analysis of a complex simulation model for mosquito population dynamics, dengue transmission, and their control.
436. First report of multiple lineages of dengue viruses type 1 in Rio de Janeiro, Brazil.
437. Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity.
438. Epidemiological aspects of exotic malaria and dengue fever in travelers in Korea.
439. Maturation of dengue virus nonstructural protein 4B in monocytes enhances production of dengue hemorrhagic fever-associated chemokines and cytokines.
440. Characterization of early host responses in adults with dengue disease.
441. Better late than never: antivirals for dengue.
442. Malaria and dengue co-infection.
443. No evidence of dengue virus circulation in rural Gabon.
444. Dengue virus infection in Africa.
445. Enzyme-linked immunosorbent assay-format tissue culture infectious dose-50 test for titrating dengue virus.
446. Histopathological diagnosis of myocarditis in a dengue outbreak in Sri Lanka, 2009.
447. Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.
448. Dengue: clinical forms and risk groups in a high incidence city in the southeastern region of Brazil.
449. Apropos "Evaluation of nonstructural 1 protein rapid test for dengue virus at the Narita Airport Quarantine Station, Japan".
450. Splenic rupture in dengue hemorrhagic fever: report of a case and review.
451. Nonstructural protein 1 antibody-based epitope-blocking enzyme-linked immunosorbent assay to differentiate Japanese encephalitis virus from dengue virus infections in humans.
452. Dengue virus infection: predictors for severe dengue.
453. First report of field evolved resistance to agrochemicals in dengue mosquito, Aedes albopictus (Diptera: Culicidae), from Pakistan.
454. DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
455. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
456. Simultaneous detection and differentiation of dengue virus serotypes 1-4, Japanese encephalitis virus, and West Nile virus by a combined reverse-transcription loop-mediated isothermal amplification assay.
457. Molecular epidemiology of autochthonous dengue virus strains circulating in Mexico.
458. Viral co-infection with dengue and H1N1 virus in a critical care setting.
459. Proteomic analysis of an Aedes albopictus cell line infected with Dengue serotypes 1 and 3 viruses.
460. Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella.
461. [Empowerment for dengue prevention and control].
462. Dengue virus infections among travelers returning from Haiti--Georgia and Nebraska, October 2010.
463. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection.
464. Downregulation of interferon-β in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6.
465. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.
466. Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells.
467. The role of climate variability and change in the transmission dynamics and geographic distribution of dengue.
468. Dengue vaccine roll-out: getting ahead of the game.
469. Estimating potential demand and supply of dengue vaccine in Brazil.
470. Contribution of dengue fever to the burden of acute febrile illnesses in Papua New Guinea: an age-specific prospective study.
471. Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors.
472. Geographical gradient of mean age of dengue haemorrhagic fever patients in northern Thailand.
473. The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal out-bred mice resulting in lethal multi-organ disease.
474. A case of dengue encephalitis with intracerebral hemorrhage.
475. A translation inhibitor that suppresses dengue virus in vitro and in vivo.
476. Full-length Dengue virus RNA-dependent RNA polymerase-RNA/DNA complexes: stoichiometries, intrinsic affinities, cooperativities, base, and conformational specificities.
477. Susceptibility status of dengue vectors against various insecticides in Koderma (Jharkhand), India.
478. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice.
479. Dengue epidemic in Malaysia: Not a predominantly urban disease anymore.
480. [Comparison of the transcriptional profiles of patients with dengue fever and dengue hemorrhagic fever reveals differences in the immune response and clues in immunopathogenesis].
481. [Efficacy of the social mobilization and the social participation in dengue control measures].
482. The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach.
483. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.
484. Age-specificity of clinical dengue during primary and secondary infections.
485. Pyrethroid resistance reduces the efficacy of space sprays for dengue control on the island of Martinique (Caribbean).
486. Molecular epidemiology of dengue viruses in southern China from 1978 to 2006.
487. Is routine dengue vector surveillance in central Brazil able to accurately monitor the Aedes aegypti population? Results from a pupal productivity survey.
488. Use of a tandem affinity purification assay to detect interactions between West Nile and dengue viral proteins and proteins of the mosquito vector.
489. Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity.
490. Dengue virus tropism in humanized mice recapitulates human dengue fever.
491. HLA class I and class II associations in dengue viral infections in a Sri Lankan population.
492. Ecological factors associated with dengue fever in a Central Highlands province, Vietnam.
493. First dengue virus detection in Aedes albopictus from Delhi, India: its breeding ecology and role in dengue transmission.
494. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health.
495. Dengue hemorrhagic fever: a rare cause of pituitary tumor hemorrhage and reversible vision loss.
496. [Perinatal dengue infection].
497. Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype.
498. Time series analysis of dengue incidence in Guadeloupe, French West Indies: forecasting models using climate variables as predictors.
499. Dengue fever continues to challenge and to puzzle.
500. Risk of dengue occurrence based on the capture of gravid Aedes aegypti females using MosquiTRAP.
501. Multiple insecticide resistance in Aedes aegypti (Diptera: Culicidae) populations compromises the effectiveness of dengue vector control in French Guiana.
502. Genetic and biological characterization of a densovirus isolate that affects dengue virus infection.
503. Dengue virus type 4 arrives in the state of Rio de Janeiro: a challenge for epidemiological surveillance and control.
504. The early clinical features of dengue in adults: challenges for early clinical diagnosis.
505. Endemic dengue associated with the co-circulation of multiple viral lineages and localized density-dependent transmission.
506. Prevalence of febrile syndromes in dengue surveillance, havana city, 2007.
507. The influence of geographic and climate factors on the timing of dengue epidemics in Perú, 1994-2008.
508. A new approach to monitoring dengue activity.
509. Using web search query data to monitor dengue epidemics: a new model for neglected tropical disease surveillance.
510. Dengue fever in a patient recovering from coronary artery bypass grafting.
511. Dengue shock.
512. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.
513. A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis.
514. Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries.
515. Dengue virus immunoglobulin M detection in a reference laboratory setting during the 2010 dengue virus outbreak on Caribbean islands.
516. Variation in vector competence for dengue viruses does not depend on mosquito midgut binding affinity.
517. Lectin switching during dengue virus infection.
518. Impairment of CD4+ T cell polarization by dengue virus-infected dendritic cells.
519. [Factors associated with incidence of dengue in Costa Rica].
520. Ovitrap surveillance of the dengue vectors, Aedes (Stegomyia) aegypti (L.) and Aedes (Stegomyia) albopictus Skuse in selected areas in Bentong, Pahang, Malaysia.
521. Spatial distribution of the risk of dengue fever in southeast Brazil, 2006-2007.
522. Dynamic RNA structures in the dengue virus genome.
523. Socio-geographical factors in vulnerability to dengue in Thai villages: a spatial regression analysis.
524. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance.
525. Wolbachia uses host microRNAs to manipulate host gene expression and facilitate colonization of the dengue vector Aedes aegypti.
526. Use of saliva for early dengue diagnosis.
527. A new approach to dengue fatal cases diagnosis: NS1 antigen capture in tissues.
528. Confirmed adult dengue deaths in Singapore: 5-year multi-center retrospective study.
529. Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.
530. Structural flexibility of the macrophage dengue virus receptor CLEC5A: implications for ligand binding and signaling.
531. Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaques.
532. Defective interfering viral particles in acute dengue infections.
533. [Sylvatic dengue: should we be worried?].
534. [Dengue virus serotypes in children of Manaus, State of Amazonas, 2008].
535. Dengue vector control strategies in an urban setting: an economic modelling assessment.
536. Design of new competitive dengue ns2b/ns3 protease inhibitors-a computational approach.
537. Economic value of dengue vaccine in Thailand.
538. Climate variability and dengue fever in warm and humid Mexico.
539. Acute dengue fever with computed tomography (CT) correlation.
540. [Targeted treatment of Aedes aegypti at localities with high risk for dengue transmission, Morelos, Mexico].
541. Aedes aegypti and Aedes albopictus (Diptera: Culicidae): coexistence and susceptibility to temephos, in municipalities with occurrence of dengue and differentiated characteristics of urbanization.
542. [Impact of the dengue epidemic due to a new lineage of DENV-2 American/ Asian genotype in the health services demand in hospital "Cesar Garayar Garcia", Iquitos].
543. [Levels of CD4 cell counts in hospitalized patients with diagnosis of dengue in hospital "César Garayar García", Iquitos].
544. [Neonatal dengue in Peru: a case report].
545. [Clinical characteristics of patients admitted to hospital "Cesar Garayar García", Iquitos during the dengue epidemic, January-February 2011].
546. [Circulation of a different lineage of dengue virus serotype 2 American / Asian genotype in the Peruvian Amazon, 2010].
547. Dengue fever in the Indian Subcontinent: an overview.
548. Oviposition site selection by the dengue vector Aedes aegypti and its implications for dengue control.
549. Dengue virus serotype 4, Roraima State, Brazil.
550. Imported dengue virus serotype 3, Yemen to Italy, 2010.
551. Upward trend in dengue incidence among hospitalized patients, United States.
552. Travel-related dengue virus infection, The Netherlands, 2006-2007.
553. [Knowledge, attitude and practice on dengue, the vector and control in an urban community of the Northeast Region, Brazil].
554. Comparison of two generations of the Panbio dengue NS1 capture enzyme-linked immunosorbent assay.
555. Spatial modeling of dengue and socio-environmental indicators in the city of Rio de Janeiro, Brazil.
556. Evaluation of nonstructural 1 protein rapid test for dengue virus at the Narita Airport quarantine station, Japan.
557. Dengue fever as an acute febrile disease after overseas travel: a report of two cases.
558. Highly conserved region 141‒168 of the NS1 protein is a new common epitope region of dengue virus.
559. Secreted dengue virus nonstructural protein NS1 is an atypical barrel-shaped high-density lipoprotein.
560. Identification of cis-acting elements in the 3'-untranslated region of the dengue virus type 2 RNA that modulate translation and replication.
561. Voronoi distance based prospective space-time scans for point data sets: a dengue fever cluster analysis in a southeast Brazilian town.
562. Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries.
563. Vaccines for the prevention of dengue: development update.
564. Serological evaluation of suspected West Nile virus human cases following its introduction during a dengue outbreak in Puerto Rico in 2007.
565. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis.
566. Changing trends of dengue disease: a brief report from a tertiary care hospital in New Delhi.
567. Impact of daily temperature fluctuations on dengue virus transmission by Aedes aegypti.
568. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis.
569. Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection.
570. Identification of a cryptic prokaryotic promoter within the cDNA encoding the 5' end of dengue virus RNA genome.
571. The F1 motif of dengue virus polymerase NS5 is involved in promoter-dependent RNA synthesis.
572. Evaluation of the effectiveness of insecticide treated materials for household level dengue vector control.
573. Dengue in Thailand and Cambodia: an assessment of the degree of underrecognized disease burden based on reported cases.
574. Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever.
575. Serologic imprint of dengue virus in urban Haiti: characterization of humoral immunity to dengue in infants and young children.
576. Dengue virus type 3 isolated from a fatal case with visceral complications induces enhanced proinflammatory responses and apoptosis of human dendritic cells.
577. Portal vein thrombosis following laparoscopic cholecystectomy complicated by dengue viral infection: a case report.
578. Dengue control: the challenge ahead.
579. Dengue disease status in Chennai (2006-2008): a retrospective analysis.
580. Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplasts.
581. N-linked glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with human complement.
582. Towards a semen proteome of the dengue vector mosquito: protein identification and potential functions.
583. Dengue causing fulminant hepatitis in a hepatitis B virus carrier.
584. Evidence on impact of community-based environmental management on dengue transmission in Santiago de Cuba.
585. Neglected lessons from the 2009 dengue epidemic in Argentina.
586. Comparative complete genome analysis of dengue virus type 3 circulating in India between 2003 and 2008.
587. Dengue infection increases the locomotor activity of Aedes aegypti females.
588. Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera.
589. Evaluation of the Dengue NS1 Ag Strip® for detection of dengue virus antigen in Aedes aegypti (Diptera: Culicidae).
590. Autochthonous dengue fever in Croatia, August-September 2010.
591. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand.
592. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam.
593. Intracerebral infection with dengue-3 virus induces meningoencephalitis and behavioral changes that precede lethality in mice.
594. NF90 binds the dengue virus RNA 3' terminus and is a positive regulator of dengue virus replication.
595. Dengue virus modulates the unfolded protein response in a time-dependent manner.
596. Genetic elimination of dengue vector mosquitoes.
597. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor.
598. Oligomeric procyanidins stimulate innate antiviral immunity in dengue virus infected human PBMCs.
599. The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry.
600. Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries.